Convalescent Plasma for Treatment of COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

SARS-CoV-2 convalescent plasma

Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay \>9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.

OTHER

Standard of care

Standard of care as determined by hospital practices for COVID-19 patients.

Trial Locations (3)

18257

Danderyd Hospital, Stockholm

79182

Department of Infectious Disease, Falu Hospital, Falun

171 76

Department of Geriatrics, Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

collaborator

Danderyd Hospital

OTHER

collaborator

Falu Hospital

OTHER

lead

Joakim Dillner

OTHER

NCT04649879 - Convalescent Plasma for Treatment of COVID-19 | Biotech Hunter | Biotech Hunter